33054-8

BCL2 Ag [Presence] in Tissue by Immune stain

Active

Term Description

BCL-2 immunopositivity has been linked to the emergence of androgen independence in metastatic prostate cancer.
Source: Regenstrief LOINC

Part Descriptions

LP28446-0   BCL2
BCL-2 immunopositivity has been linked to the emergence of androgen independence in metastatic prostate cancer. Source: Regenstrief Institute

LP28446-0   BCL2
Bcl-2 (B-cell lymphoma 2) is the founding member of the Bcl-2 family of apoptosis regulator proteins encoded by the BCL2 gene. Bcl-2 derives its name from B-cell lymphoma 2, as it is the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas. Bcl-2 orthologs have been identified in numerous mammals for which complete genome data are available. The two isoforms of Bcl-2, Isoform 1, also known as 1G5M, and Isoform 2, also known as 1G5O/1GJH, exhibit similar fold. However, results in the ability of these isoforms to bind to the BAD and BAK proteins, as well as in the structural topology and electrostatic potential of the binding groove, suggest differences in antiapoptotic activity for the two isoforms.

The Bcl-2 gene has been implicated in a number of cancers, including melanoma, breast, prostate, chronic lymphocytic leukemia, and lung carcinomas, as well as schizophrenia and autoimmunity. It is also thought to be involved in resistance to conventional cancer treatment. This suggests that decreased apoptosis may play a role in the development of cancer.

Antibodies to Bcl-2 can be used with immunohistochemistry to identify cells containing the antigen. In healthy tissue, these antibodies will react with B-cells in the mantle zone, as well as some T-cells. However, there is a considerable increase in positive cells in follicular lymphoma, as well as many other forms of cancer. In some cases, the presence or absence of Bcl-2 staining in biopsies may be significant for the patient's prognosis or likelihood of relapse. Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details. Source: Wikipedia, Wikipedia

Fully-Specified Name

Component

BCL2 Ag

Property

PrThr

Time

Pt

System

Tiss

Scale

Ord

Method

Immune stain

Additional Names

Short Name

BCL2 Ag Tiss Ql ImStn

Display Name

BCL2 Ag Immune stain Ql (Tiss)

Consumer Name Alpha Get Info

BCL2 antigen, Tissue

Basic Attributes

Class

PATH

Type

Laboratory

First Released

Version 2.09

Last Updated

Version 2.73

Change Reason

The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.

Order vs. Observation

Both

Common Test Rank Get Info

13737

Language Variants Get Info

Related Names

• Antigen
• Antigens
• B-cell leukemia/lymphoma 2
• BCL-2
• IHC
• Imm
• Immunohistochemical stain
• Immunostain
• ImStn
• Imun
• Imune
• Ordinal
• PATHOLOGY
• Point in time
• PR
• QL
• Qual
• Qualitative
• Random
• Screen
• St
• Stains
• Stn
• Tissue
• Tissue, unspecified

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.

CodeSystem lookup

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=33054-8

LOINC Copyright

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.